Can a Weight-Loss drug stop obesity before it starts? new trial aims to find out
NCT ID NCT06905626
First seen Jan 17, 2026 · Last updated Jun 23, 2026 · Updated 22 times
Summary
This study tests whether the drug Qsymia, combined with lifestyle coaching, can prevent obesity in 140 adolescents and young adults (ages 18-25) who are overweight (BMI 25-30) and have a family history of obesity. Participants will receive either Qsymia or a placebo, plus coaching on diet and exercise, for about one year. The main goal is to see if the drug helps maintain a healthy body mass index.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Qsymia (phentermine and topiramate extended-release)
What this could lead to
If successful, this could provide a proven way to prevent obesity in young people at high risk, reducing future health problems.
What could go wrong
This is a relatively small Phase 3 trial, and the drug may cause side effects. Results may not apply to all groups, and long-term safety is still being studied.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.